Company news
InnoCan Pharma Corporation news in 2025
InnoCan Pharma Corporation's news releases, calls and decks from 2025, newest first.
Innocan Pharma Announces Public Filing of Amended Registration Statement for Proposed U.S. Public Offering
December 10, 2025
Innocan Pharma Reports Financial Results for Q3 2025, with Revenues at US $21.6M
November 27, 2025
Financial Statements as of September 30, 2025
November 26, 2025
MD&A Report For Nine Months Period Ended September 30, 2025
November 26, 2025
Innocan Pharma Announces Promising Translational Evidence from a Pain Relief Study of Repeated LPT-CBD Administration in Goats
November 24, 2025
Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
November 20, 2025
Innocan Pharma to Present at the 2025 ThinkEquity Conference
October 24, 2025
Liposomal CBD Injection Technology (LPT-CBD) patent was allowed in Japan
October 15, 2025
Innocan Pharma Partners With a Sanctuary For Injured Animals to Bring Remedy and Hope with its LPT-CBD injection
September 18, 2025
Innocan Pharma's Poster on its Liposomal Synthetic CBD Technology Generates Interest at PAINWeek Conference
September 15, 2025
CSE Bulletin: Consolidation - InnoCan Pharma Corporation (INNO)
September 2, 2025
Innocan Pharma Announces Details of Proposed Share Consolidation
August 29, 2025
MD&A Report For Six Months Period Ended June 30, 2025
August 28, 2025
Financial Statements as of June 30, 2025
August 28, 2025
Innocan Pharma Announces First Half Of 2025 Financial Results
August 27, 2025
Innocan's Findings to be Showcased in Scientific Poster Reception at PAINWeek 2025 Conference in Las Vegas, Nevada
August 22, 2025
Innocan Pharma Announces Public Filing of Registration Statement for Proposed U.S. Public Offering
July 23, 2025
Innocan Pharma Announces Promising Results of LPT-CBD Administered to Gottingen Minipigs, providing a good translational model and Provides Corporate Update
July 3, 2025
Innocan Pharma Announces Presentation of Narrative Review on Long-Acting Synthetic Cannabidiol for Chronic Pain at PAINWEEK Conference
June 20, 2025
Innocan Pharma Highlights Breakthrough Narrative Review on Liposomal Synthetic CBD for Chronic Pain: A Novel Non-Opioid Analgesic Approach
June 13, 2025
Innocan Pharma Announces First Quarter 2025 Financial Results with Continued Strong Revenue Growth and Provides Corporate Update
May 28, 2025
Innocan Pharma First Granted Patent in Mexico for its Topical Pain Relief
May 6, 2025
Innocan Pharma Announces Closing of Private Placement
April 15, 2025
Innocan Pharma Broadens Intellectual Property Coverage for its Liposomal CBD Injection Across Asia and Announces Private Placement of Units
April 7, 2025
Innocan Pharma Reports Full Year 2024 Results with Revenues more than Doubling to US $29.4 million
March 31, 2025
Innocan Pharma Announces Closing of Debenture Unit Offering to its Largest Shareholder, Tamar Innovest Limited
March 7, 2025
Innocan Pharma Announces Private Placement Offering of a Debenture Unit to its Largest Shareholder, Tamar Innovest
February 27, 2025